SynteractHCR is a full-service CRO with a successful two-decade track record supporting biopharmaceutical and medical device companies through the clinical development process. We have conducted Phase I-IV studies on six continents and 60+ countries, in multiple therapeutic areas. Our “Shared Work – Shared Vision” approach helps bring tomorrow’s treatments to patients.
Products and Services
Orphan Indications and Clinical Trials: Why Rare Diseases Warrant Special Treatment
SynteractHCR latest white paper highlights the need to give rare diseases special treatment
Cancer Immunotherapy and Other Advanced Therapies: Opportunity and Challenges Combine to Bring Tomorrow’s Treatments to Patients
SynteractHCR examines cancer immunotherapy as well as various other advanced therapies
The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
SynteractHCR assesses the strengths and weaknesses of the new EU Clinical Trials Regulation